Based on the initial trial findings, PD-1/PD-L1 inhibitors have shown clinical efficacies against many different solid and hematologic malignancies, including NSCLC, melanoma, renal cell cancer and others [9–12]. Here, PDCD1 is linked to renal cell adenocarcinoma.